Articles from Investor Brand Network

Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled “Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods,” further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs.

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is starting the new year with a bang: the company is ranked no. 2 on the HotCars 2022 list of top-10 EV startups ( https://ibn.fm/Gb5IR ). Other online callouts have noted that Mullen is “making performance EVs to get excited about” ( https://ibn.fm/anGC4 ) and have called Mullen “Tesla’s next potential competitor” ( https://ibn.fm/5Bi4C ).

Lexaria Bioscience (NASDAQ: LEXX) has made a name for itself as a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) technology, promotes fast-acting, less expensive, and more effective oral drug delivery, proven through in vivo, in vitro, and human clinical testing.

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance MMT(R) lidar solutions, announced the appointment of Paul Anawalt to the newly created position of general counsel, effective today. Anawalt joins Cepton from the Intel Corporation and is a seasoned lawyer with more than 25 years of business and technology law experience, serving as in-house and outside counsel. He has advised public and private companies on strategy, technology transactions, IP, securities, mergers and acquisitions and other areas. “I am grateful for the opportunity to lead the legal organization of Cepton and excited to help strengthen Cepton’s business and develop our legal strategy to support our planned growth,” Anawalt said in the press release. “I look forward to being a part of Cepton’s journey in providing lidar-based solutions for a range of markets.”

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that its Robot Roadshow will land at the Hollywood Casino in Aurora, Illinois, on April 19-20 from 10:00 a.m. to 2:00 p.m. CT, and at Digby’s Detective & Security Agency in Chicago, Illinois, on April 21, 2022, from 10:00 a.m. to 2:00 p.m. CT. A Knightscope expert virtually attends each Roadshow landing, and visitors will have the opportunity to see the Knightscope Security Operations Center (“KSOC”) user interface in action and interact directly with each of the company’s autonomous security robots.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded at a new 12-month high today of $46.97. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 5.2 million shares.

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of all products made by Bidi(R) Vapor LLC, including the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”), is expanding its distribution by adding both wholesale and retail accounts. Kaival anticipates the new distribution footprint will cover an estimated 28,000 additional stores. The announcement comes after the U.S. Food and Drug Administration issued a marketing denial order (“MDO”) to Bidi Vapor last year, as it did for some 96% of all manufacturers of flavored ENDS. However, earlier this year the U.S. Court of Appeals for the Eleventh Circuit granted Bidi Vapor a judicial stay of the MDO, while the courts determine the result of Bidi Vapor’s ongoing merits-based litigation. “We are encouraged by growing sales volumes in our second fiscal quarter generated by both established wholesalers and retailers selling the BIDI Stick in new stores, as well as new wholesale and retail accounts being added to our distribution network,” said Kaival Brands CEO Niraj Patel in the press release. “We anticipate the activation of approximately 3,900 new store locations over the next 45 days, including one new major retailer having already placed orders totaling more than $1.1 million. . . . The judicial stay granted in February allowed us to resume sale of all 11 flavored products in the BIDI Stick lineup. We are eager to return our flavored products to the shelves of retailers that comply with the Prevent All Cigarette Trafficking Act so adult consumers can enjoy their preferred flavors once again. As a result of the judicial stay, we expect revenues to resume an upward trajectory as renewed distribution ramps up and sales of flavored BIDI Sticks increase.”

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the coming months as its next revenue generators…. The company expects to produce more than 100 kilograms of CBDV and THCV under the initiative. Because of the very limited quantities of rare cannabinoids that make them effectively impractical from an economic standpoint to extract directly from the plant for pharmaceutical use, InMed’s R&D operation is working to develop synthetic formulations for the treatment of specific conditions.”

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, recently completed for what all purposes was a truly banner year for the company. SRAX achieved $46.1 million in bookings for 2021, whilst simultaneously boosting the number of issuers currently subscribing to the Sequire platform to 278 publicly listed corporations. Meanwhile and during the company’s recent annual earnings call on April 4, 2022, SRAX CEO Chris Miglino boosted the company’s full year 2022 revenue guidance to $47 million – $49 million – a further affirmation of SRAX’s positive corporate outlook going forward ( https://ibn.fm/mYKQ0 ).

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (“PASP”) with DehydraTECH-CBD treatment versus placebo. According to the announcement, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, which could indicate potential differences by sex in responsiveness to CBD treatment under hypoxic stress conditions. The company noted that this data supports similar findings from previous successful studies, all of which support Lexaria’s anticipated move to begin the process of seeking approval for the technology from the U.S. Food and Drug Administration. The company has gathered significant evidence of DehydraTECH-CBD’s ability to reduce blood pressure across a wide variety of situations. The data from the most recent study will be analyzed in order to determine the direction of the company’s upcoming research looking into the efficacy of DehydraTECH-CBD use for the management of elevations in pulmonary arterial pressure under hypoxic conditions, related hypoxemic pathologies and pulmonary hypertension.

In its 2022 State of Protective Intelligence Report, which surveyed security professionals, legal officers, compliance officers, and corporate attorneys at U.S. companies with more than 5,000 employees, the Ontic Center for Protective Intelligence (“OCPI”) noted that 88% of the respondents maintain that their companies are experiencing a substantial uptick in physical threat activity that is expected to grow even further as the year progresses ( https://ibn.fm/LPpq5 ).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), was spotlighted in an episode of the Power Play by the Market Herald. Cybin CEO Doug Drysdale talked with host Dave Jackson about the company’s recent positive results from its CYB004 pharmacokinetic study. The company announced that the study produced positive preclinical data demonstrating that when inhaled, Cybin’s deuterated dimethyltryptamine (“DMT”) molecule indicated advantages, such as a longer duration of action and improved bioavailability, over both IV DMT and inhaled DMT. Power Play interviews with company executives offer investors a quick snapshot of an array of companies, along with a look at each company’s latest news.

A recent Mordor Intelligence article is reporting that the global rare earth elements (“REE”) market has reached an estimated 161,354.65 tons this year, with an expected compound annual growth rate (“CAGR”) of more than 4% between now and 2027 ( https://ibn.fm/6UppN ). That growth could prove beneficial to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), a leading U.S.-based uranium mining company that is also moving faster than any other company to re-establish a domestic REE supply chain.

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“pk”) randomized, double blinded, cross-over study to compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands currently sold in the U.S. such as ON! and Zyn. Lexaria hopes to evidence that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to brands currently on the market. The study’s primary objective is data collection from blood samples that will evidence Tmax, Cmax and AUC. Secondary objectives of the study include extensive subjective evaluations related to throat burn, user experience and more. The design phase of NIC-H22-1 is complete, and test articles are currently being manufactured. Funding NIC-H22-1 with existing capital, the company is optimistic that this larger study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose.

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, hit a critical mineral “trifecta” this month, making commercial shipments of uranium, vanadium and advanced rare earth materials — all in a single week. According to the announcement, the company shipped natural uranium concentrates (“U308”) to the Metropolis Works uranium conversion facility in Metropolis, Illinois; vanadium pentoxide (“V205”) to the Bear Metallurgical Company in Butler, Pennsylvania; and high-purity mixed rare earth element (“REE”) carbonate to the Neo Performance Materials facility in Estonia. “I believe the week of April 4, 2022, will go down as one of the most important weeks in company history,” said Energy Fuels CEO and president Mark Chalmers in the press release. “This week, our vision of Energy Fuels as ‘America’s Critical Mineral and Clean Energy Hub’ tangibly advanced, as our White Mesa Mill in Utah sent three shipments of advanced materials containing a total of 15 critical elements, including the rare earth elements cerium, praseodymium, neodymium, samarium, europium, gadolinium, dysprosium, terbium, holmium, yttrium, erbium, thulium, ytterbium, and lutetium, along with uranium and vanadium, to downstream processing facilities. We sent a shipment of high-purity rare earth carbonate containing 32%–34% NdPr to Silmet in Estonia, where it will be refined and processed into various advanced materials for use in permanent magnets used in electric vehicle motors and wind generation, batteries, electronics, defense applications, and other technologies. We sent a shipment of uranium concentrates to ConverDyn in Illinois for sale to U.S. nuclear utilities for the production of carbon-free nuclear energy, and further adding to Energy Fuels’ industry-leading finished U.S.-origin uranium inventory. And we sent another truckload of vanadium to Bear Met in Pennsylvania for conversion into ferrovanadium for use in high-strength steel and other advanced and specialty alloys. I could not be more proud of what our team is doing at the White Mesa Mill on rare earths.”

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (“DMT”) molecule, CYB004, delivered via inhalation. According to the announcement, inhaled CYB004 demonstrated significant advantages over both intravenous and inhaled DMT, including longer duration of action and improved bioavailability. The study also demonstrated that inhaled CYB004 showed a similar dose profile and onset of effect to IV DMT. “In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability,” said Doug Drysdale, chief executive officer of Cybin. “CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic. As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians.”

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has completed the System and Organization Controls (“SOC”) 2 Type 2 certification audit. The audit, which started in November 2021, focused on controls relevant to the security trust services category. According to the announcement, SOC 2 Compliance is a recognized auditing standard developed by the American Institute of Certified Public Accountants (“AICPA”) that evaluates a service organization’s systems and determines if specified controls meet relevant trust services categories. Considered the gold standard for establishing trust with customers, the audit also measures the effectiveness of those controls over a specified period of time. “GreenBox customers rely on our customized payment-solutions software as the lifeline for their businesses,” said Greenbox CEO Fredi Nisan in the press release. “This requires the trust and integrity of our security, controls and risk management processes as well as strict adherence to compliance. By completing the SOC 2 type 2 certification, not only do we align ourselves with the industry standards followed by world class organizations, but given our strong growth trajectory, it is indicative of our commitment to protecting both our internal and external constituents while building trust with rigorous control processes and prudent risk management.”

GreenBox (NASDAQ: GBOX), an emerging and rapidly growing fintech company, has named a new member of its board of directors. The company has appointed transactional lawyer Adele Hogan to the board; Hogan will replace Carl Williams. With more than three decades of experience, Hogan has been involved in an estimated $200 billion of securities, mergers, contracts and closed deals. She is currently a partner at Lucosky Brookman, where she also serves as the cochair of the Corporate, Mergers & Securities Practice Group overseeing mergers and capital markets transactions including IPOs, SPACs, de-SPACs, corporate side of bankruptcies, securities and derivatives. Previously she has been a partner at Hogan Law Associates, where she managed complex mergers, securities offerings, derivatives and financing deals. In addition, she is committed to education, teaching, chairing, and speaking at board associations and Fordham University; she also regularly judges transactional law competitions at Cornell Law School. “Adele is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout her legal career,” said Greenbox chair Ben Errez in the press release. “She is a partner at our securities law firm and has been material to recent acquisitions and securities compliance successes, and will be an important contributor to any M&A and dividend plans. She will be an affiliated board member, bringing the balance in the Board to three affiliated and four independent members. We welcome Adele to the Board and look forward to her contributions as we continue to strengthen and scale our business by integrating and leveraging our recent acquisitions into becoming a truly comprehensive global payment solutions leader.”

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has entered agreements with Altria Client Services LLC. According to the announcement, the agreements call for Lexaria to provide specific DehydraTECH(TM) powder-based nicotine formulations for a fee; Altria in turn will evaluate the formulations. The new agreements will continue through March 31, 2023. Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. In addition, the technology has shown the ability to increase bioabsorption with cannabinoids and nicotine by up to 10 times as well as decrease time of onset significantly.

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies committed to enhancing U.S. security operations, has promoted four employees to executive positions. Doris Lam has been named vice president of finance, Jason M Gonzalez has been named senior vice president of client development, Ronald J Gallegos has been named vice president of client experience and Ryan J Fanciullo has been named vice president of operations. According to the announcement, these employees have demonstrated exceptional leadership abilities and have been promoted to capitalize on Knightscope’s current momentum as the company continues focusing on product innovation and sales growth. The new management leads have proven expertise in identifying and executing mission-critical solutions that have driven better operational results, streamlined administrative workflows, accelerated capital formation and increased sales pipeline engagement.

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and will include CNS Pharmaceuticals management team members, including CEO John Climaco, along with opinion leader Samuel A. Goldlust, MD. The focus of the chat will be GBM and the work that CNS Pharmaceuticals is doing to advance Berubicin, its novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier for the treatment of recurrent GBM, one of the most aggressive types of brain cancer. The company is currently conducting a global study evaluating the efficacy and safety of Berubicin in the treatment of GBM. Goldlust is Dr. Goldlust is an investigator in the company’s Berubicin study and a leading neuro-oncologist who currently serves as the Pitkin chair in neuro-oncology and as medical director of the Brain and Spine Institute at John Theurer Cancer Center.

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced that CEO Luis Merchan will be presenting at the upcoming Benzinga Cannabis Capital Conference. The event is scheduled for April 20–21, 2022, in Miami, Florida. Merchan’s presentation is slated to begin at 3:20 p.m. ET on April 20. In addition to Merchan’s presentation, members of Flora’s management team will be scheduling one-on-one investor meetings throughout the day. The Benzinga Cannabis Capital Conference gathers together more than 1,000 of the top movers and shakers in the cannabis industry and offers an invaluable opportunity for companies operating in the cannabis space to raise money, create partnerships and expand media visibility. The event agenda includes insightful keynote presentations, panel discussions, fireside chats, networking and company presentations as well as investor and celebrity appearances; this year’s event also features a larger exhibit floor and enhanced industry networking opportunities. “We’re looking forward to presenting at the Benzinga Cannabis Capital Conference and sharing valuable insights into our company and the industry as a whole with the attendees,” said Flora Growth CEO Luis Merchan in the press release. “Few events offer a lineup and networking opportunities as Benzinga does.”

More than a decade after the Tesla Roadster launched and proved that electric vehicles were commercially viable, the nascent electric vehicle industry is slowly filling up with competition . Gone are the days where the only player in the EV game was Tesla; legacy auto makers and several EV startups have now thrown their hats into the ring in a bid to snag a portion of the lucrative electric vehicle market.

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using DehydraTECH’s advanced drug delivery capabilities, Lexaria hopes to demonstrate superior performance in the research program. The company expects to achieve significant gains in systemic delivery and brain uptake – which have been evidenced and announced from other studies comparing the DehydraTECH 2.0 CBD formulations with concentration-matched controls. Lexaria believes this could improve therapeutic efficacy for multiple conditions of the nervous system, including but not limited to epilepsy.”

Shares of General Mills Inc. (NYSE:GIS) traded at a new 12-month high today of $70.94. So far today approximately 489,000 shares have been exchanged, as compared to an average 30-day volume of 4.1 million shares.